Amwell (AMWL) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $56.3 million, an 8% decrease year-over-year, primarily due to the divestiture of Amwell Psychiatric Care (APC) and reduced contributions from Leidos. Normalized revenue would have increased by 1.3%.

Subscription Revenue: $30.9 million, up 18% year-over-year, now representing 55% of total revenue (compared to 43% last year).

Visit Volume: Approximately 1.1 million visits, down 21% year-over-year, but aligned with expectations. Amwell Medical Group (AMG) visit revenue decreased by 23% to $21.2 million.

Average Revenue per Visit: $71, a 14% decline year-over-year, but normalized for APC sale, it showed a 3.5% increase.

GAAP Gross Margin: Expanded to 52% from 37% year-over-year.

Operating Expenses: $58.9 million, a 16% decrease from last year, with significant reductions in R&D (6%), sales and marketing (46%), and G&A (14%).

Adjusted EBITDA: Loss of $12.7 million, improved from a loss of $31 million a year ago.

Cash Position: Approximately $201 million in cash and marketable securities, with no debt.

2Strategic Updates and Business Highlights

Amwell is focused on achieving cash flow breakeven by the end of 2026 through two main initiatives: enhancing their enterprise-grade platform and improving operational efficiency.

The integration of AI technologies is central to their strategy, aimed at transforming patient intake and clinical program matching.

The company is divesting non-core assets to concentrate resources on high-margin growth opportunities, with a commitment to maintain support for legacy products during the transition.

Positive market trends include increased consumer demand for digital health solutions and a growing recognition of the need for integrated care solutions among health systems.

3Forward Guidance and Outlook

Full Year Revenue Guidance: Expected between $245 million and $248 million, slightly revised down from the previous range.

Adjusted EBITDA Guidance: Projected loss between $45 million and $42 million, improved from prior estimates.

Q4 Revenue Guidance: Anticipated between $51 million and $54 million, with adjusted EBITDA losses between $15 million and $12 million.

The company aims to reduce R&D expenses by over 10% and sales and marketing costs by more than 25% year-over-year.

4Bad News, Challenges, or Points of Concern

Declining Visit Volume: A 21% year-over-year decrease in total visit volume raises concerns about demand and utilization of services.

Revenue Decline: Overall revenue decline, particularly from key partnerships, could indicate challenges in customer retention and market competitiveness.

Market Fragmentation: While there is growing demand for integrated solutions, the complexity and fragmentation in the digital health market pose risks for customer acquisition and retention.

Economic Uncertainty: Potential impacts from macroeconomic factors and health systems evaluating IT budgets may affect future sales pipelines.

5Notable Q&A Insights

Competitive Wins: Amwell's recent win with Florida Blue was attributed to their ability to provide a unified platform that reduces vendor fatigue and complexity, indicating a competitive edge in the market.

Divestiture Strategy: The company is actively pursuing the divestiture of non-core assets to focus on high-ROI opportunities, although these actions are not yet reflected in current guidance.

AI Monetization: AI integration is expected to enhance customer ROI through improved patient experiences and operational efficiencies, although immediate pricing impacts are not anticipated.

Customer Retention Focus: Retaining existing clients is prioritized as a key factor for achieving cash flow breakeven, with a strong emphasis on delivering measurable economic value. Overall, Amwell is navigating a challenging environment with strategic initiatives aimed at long-term growth, while addressing immediate financial pressures and market dynamics.